Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Sudden Cardiac Death

  • Author: Ali A Sovari, MD, FACP; Chief Editor: Jeffrey N Rottman, MD  more...
 
Updated: Apr 28, 2014
 

Practice Essentials

Sudden cardiac death (SCD) is an unexpected death due to cardiac causes that occurs in a short time period (generally within 1 hour of symptom onset) in a person with known or unknown cardiac disease. It is estimated that more than 7 million lives per year are lost to SCD worldwide, including over 300,000 in the United States. See the image below.

Interplay of various risk factors that can lead to Interplay of various risk factors that can lead to sudden cardiac death.

Signs and symptoms

Patients at risk for SCD may have prodromes of chest pain, fatigue, palpitations, and other nonspecific complaints. Factors relating to the development of coronary artery disease (CAD) and, subsequently, myocardial infarction (MI) and ischemic cardiomyopathy include the following:

  • Family history of premature coronary artery disease
  • Smoking
  • Dyslipidemia
  • Hypertension
  • Diabetes
  • Obesity
  • Sedentary lifestyle

Specific factors relating to cardiovascular disease are listed below.

Coronary artery disease

  • Previous cardiac arrest
  • Syncope
  • Prior myocardial infarction, especially within 6 months
  • Ejection fraction of less than 30-35%
  • History of frequent ventricular ectopy: More than 10 premature ventricular contractions (PVCs) per hour or nonsustained ventricular tachycardia (VT)

Dilated cardiomyopathy

  • Previous cardiac arrest
  • Syncope
  • Ejection fraction of less than 30-35%
  • Use of inotropic medications

Hypertrophic cardiomyopathy

  • Previous cardiac arrest
  • Syncope
  • Family history of SCD
  • Symptoms of heart failure
  • Drop in systolic blood pressure (SBP) or ventricular ectopy upon stress testing
  • Palpitations
  • Most persons are asymptomatic

Valvular disease

  • Valve replacement within past 6 months
  • Syncope
  • History of frequent ventricular ectopy
  • Symptoms associated with severe, uncorrected aortic stenosis or mitral stenosis

Long QT syndrome

  • Family history of long QT and SCD
  • Medications that prolong the QT interval
  • Bilateral deafness

See Clinical Presentation for more detail.

Diagnosis

Laboratory studies

  • Cardiac enzymes (creatine kinase, myoglobin, troponin)
  • Electrolytes, calcium, and magnesium
  • Quantitative drug levels (quinidine, procainamide, tricyclic antidepressants, digoxin): High or low drug levels may have a proarrhythmic effect
  • Toxicology screen: For drugs, such as cocaine, that cause vasospasm-induced ischemia
  • Thyroid-stimulating hormone
  • Brain natriuretic peptide (BNP)

Other tests to evaluate or predict risk of SCD

  • Imaging studies: Chest radiography, echocardiography, nuclear scintigraphy
  • Electrocardiography (ECG): Including, possibly, signal-averaged ECG
  • Coronary angiography
  • Electrophysiology

See Workup for more detail.

Management

In general, advanced cardiac life support (ACLS) guidelines should be followed in all cases of sudden cardiac arrest (SCA).

Bystander cardiopulmonary resuscitation (CPR)

Immediate chest compression and defibrillation are reportedly the most important interventions to improve the outcome in SCA. Research indicates that bystander use of automated external defibrillators increases neurologically intact survival to discharge (14.3% without bystander defibrillation; 49.6% with defibrillation).[1]

Pharmacologic therapy

Medications used in SCD include the following:

  • Ventricular arrhythmia: Epinephrine or vasopressin; amiodarone and lidocaine can be used as antiarrhythmic drugs if defibrillation does not control the arrhythmia
  • Pulseless electrical activity (PEA): Epinephrine; atropine used in case of bradycardia
  • Asystole: One study suggested that vasopressin is more effective in acute therapy for asystole than epinephrine [2]
  • Medical stabilization: Empiric beta blockers are reasonable in many circumstances

Therapeutic hypothermia

This intervention limits neurologic injury associated with brain ischemia during a cardiac arrest and reperfusion injury associated with resuscitation.[3]

Surgery

  • Temporary cardiac pacing
  • Radiofrequency ablation
  • Cardioverter defibrillator therapy
  • Coronary artery bypass grafting (CABG)
  • Excision of ventricular tachycardia foci
  • Excision of left ventricular aneurysms
  • Aortic valve replacement
  • Orthotopic heart transplantation

See Treatment for more detail.

Next

Background

Sudden cardiac death (SCD) is an unexpected death due to cardiac causes occurring in a short time period (generally within 1 h of symptom onset) in a person with known or unknown cardiac disease. Most cases of SCD are related to cardiac arrhythmias. Approximately half of all cardiac deaths can be classified as SCDs. SCD represents the first expression of cardiac disease in many individuals who experience out-of-hospital cardiac arrest.

This article explores the epidemiology and pathophysiology of SCD. It also discusses the diagnostic approach to patients at risk for SCD, as well as the prevention of SCD and the treatment of sudden cardiac arrest.

Previous
Next

Pathophysiology

The most common electrophysiologic mechanisms leading to SCD are tachyarrhythmias such as ventricular fibrillation (VF) or ventricular tachycardia (VT). Interruption of tachyarrhythmias, using either an automatic external defibrillator (AED) or an implantable cardioverter defibrillator (ICD), has been shown to be an effective treatment for VF and VT.[4] The implantable defibrillator has become the central therapeutic factor in the prevention and treatment of sudden cardiac death. Patients with tachyarrhythmias, especially VT, carry the best overall prognosis among patients with sudden cardiac arrest (SCA).

There are multiple factors at the organ (eg imbalance of autonomic tone), tissue (eg reentry, wave break, and action potential duration alternans), cellular (eg triggered activity, and automaticity) and subcellular (abnormal activation or deactivation of ion channels) level involved in generation of VT or VF in different conditions. An anatomical or a functional block in the course of impulse propagation may create a circuit with the wave front circling around it and resulting in VT. Other mechanisms such as wave break and collisions are involved in generating VF from VT. While at the tissue level the above-mentioned reentry and wave break mechanisms are the most important known mechanisms of VT and VF, at the cellular level increased excitation or decreased repolarization reserve of cardiomyocytes may result in ectopic activity (eg automaticity, triggered activity), contributing to VT and VF initiation.

At the subcellular level, altered intracellular Ca2+ currents, altered intracellular K+ currents (especially in ischemia), or mutations resulting in dysfunction of a sodium channel (Na+ channelopathy) can increase the likelihood of VT and VF.

Approximately 20-30% of patients with documented sudden death events have bradyarrhythmia or asystole at the time of initial contact. Oftentimes, it is difficult to determine with certainty the initiating event in a patient presenting with a bradyarrhythmia because asystole and pulseless electrical activity (PEA) may result from a sustained VT. Less commonly, an initial bradyarrhythmia producing myocardial ischemia may then provoke VT or VF.

Most cases of SCD occur in patients with structural abnormalities of the heart. Myocardial infarction (MI) and post-MI remodeling of the heart is the most common structural abnormality in patients with SCD. In patients who survive a myocardial infarction, the presence of premature ventricular contractions (PVCs), particularly complex forms such as multiform PVCs, short coupling intervals (R-on-T phenomenon), or VT (salvos of 3 or more ectopic beats), reflect an increased risk of sudden death. However suppression of the PVCs with antiarrhythmic drugs increases mortality, owing to the proarrhythmic risk of currently available medications.

Hypertrophic cardiomyopathy and dilated cardiomyopathy are associated with an increased risk of SCD. Various valvular diseases such as aortic stenosis are associated with increased risk of SCD. Acute illnesses, such as myocarditis, may provide both an initial and sustained risk of SCD due to inflammation and fibrosis of the myocardium.

Less commonly, SCD happens in patients who may not have apparent structural heart disease. These conditions are usually inherited arrhythmia syndromes.

Even though many patients have anatomic and functional cardiac substrates that predispose them to develop ventricular arrhythmias, only a small percentage develop SCD. Identifying the patients at risk for SCD remains a challenge. The strongest known predictor of SCD is significant left ventricular dysfunction of any cause. The interplay between the regional ischemia, LV dysfunction, and transient inciting events (eg, worsened ischemia, acidosis, hypoxemia, wall tension, drugs, metabolic disturbances) has been proposed as being the precipitator of sudden death (see the image below).

Interplay of various risk factors that can lead to Interplay of various risk factors that can lead to sudden cardiac death.
Previous
Next

Epidemiology

Frequency

United States

SCD accounts for approximately 325,000 deaths per year in the United States; more deaths are attributable to SCD than to lung cancer, breast cancer, or AIDS. This represents an incidence of 0.1-0.2% per year in the adult population. SCD is often the first expression of CAD and is responsible for approximately 50% of deaths from CAD.

In several population-based studies, the incidence of out-of-hospital cardiac arrest has been noted as declining in the past 2 decades, but the proportion of sudden CAD deaths in the United States has not changed. A high incidence of SCD occurs among certain subgroups of high-risk patients (congestive heart failure with ejection fraction < 30%, convalescent phase after myocardial infarction, patients who survived cardiac arrest). However, these populations are much smaller than patients with minimal or even inapparent coronary artery disease. Consequently, in the overall population, most SCD occurs in lower risk patients. The time dependence of risk for SCD has been noted in several studies, with an increased number of events in the first 6-24 months after surviving a major cardiovascular event.

International

The frequency of SCD in Western industrialized nations is similar to that in the United States. The incidence of SCD in other countries varies as a reflection of the prevalence of coronary artery disease or other high-frequency cardiomyopathies in those populations. The trend toward increasing SCD events in developing nations of the world is thought to reflect a change in dietary and lifestyle habits in these nations. It has been estimated that SCD claims more than 7,000,000 lives per year worldwide.[5]

Mortality/Morbidity

Of more than 300,000 deaths attributed to SCD in the United States each year, a large portion (as many as 40%) are unwitnessed. For most people who experience SCD, their survival depends on the presence of individuals who are competent in performing basic life support, the rapid arrival of personnel and apparatus for defibrillation and advanced life support, and transfer to a hospital. Even under ideal circumstances, only an estimated 20% of patients who have out-of-hospital cardiac arrest survive to hospital discharge. In a study of out-of-hospital cardiac arrest survival in New York City, only 1.4% of patients survived to hospital discharge. Other studies in suburban and rural areas have indicated higher rates of survival (as high as 35%). Placement of automatic external defibrillators throughout communities and training people to use them has the potential to markedly improve outcomes from SCD.

  • Upon emergency department (ED) presentation, the most important determinants of survival include (1) an unsupported systolic blood pressure (SBP) greater than 90 mm Hg, (2) a time from loss of consciousness to return of spontaneous circulation (ROSC) of less than 25 minutes, and (3) some degree of neurological responsiveness.
  • A major adverse outcome from a SCD event is anoxic encephalopathy, which occurs in 30-80% of cases.

Race

Most studies demonstrate inconclusive data with regard to racial differences as they relate to the incidence of sudden death. Some studies suggest that a greater proportion of coronary deaths were "sudden" in blacks compared to whites. In a report by Gillum et al on SCD from 1980-1985, the percentage of coronary artery disease deaths occurring out of the hospital and in EDs was found to be higher in blacks than in whites (see the image below).[6]

Cardiac death, sudden. Plots of mortality rates (d Cardiac death, sudden. Plots of mortality rates (deaths per 1000 persons) for ischemic heart disease occurring out of the hospital or in the emergency department (top) and occurring in the hospital (bottom) by age, sex, and race in 40 states during 1985.

Sex

Men have a higher incidence of SCD than women, with a ratio of 3:1. This ratio generally reflects the higher incidence of obstructive coronary artery disease in men. Recent evidence suggests that a major sex difference may exist in the mechanism of myocardial infarction. Basic and observational data point to the fact that men tend to have coronary plaque rupture, while women tend to have plaque erosion. Whether this biologic difference accounts for the male predominance of SCD is unclear.

Age

The incidence of SCD parallels the incidence of coronary artery disease, with the peak of SCD occurring in people aged 45-75 years. The incidence of SCD increases with age in men, women, whites, and nonwhites as the prevalence of coronary artery disease increases with age. However, the proportion of deaths that are sudden from coronary artery disease decreases with age. In the Framingham study, the proportion of coronary artery disease deaths that were sudden was 62% in men aged 45-54 years, but this percentage fell to 58% in men aged 55-64 years and to 42% in men aged 65-74 years.[7] According to Kuller et al, 31% of deaths are sudden in people aged 20-29 years.[8]

Previous
 
 
Contributor Information and Disclosures
Author

Ali A Sovari, MD, FACP Fellow in Clinical Cardiac Electrophysiology, Cedars Sinai Medical Center/Heart Institute

Ali A Sovari, MD, FACP is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Physician Scientists Association, American Physiological Society, Biophysical Society, Heart Rhythm Society, Society for Cardiovascular Magnetic Resonance

Disclosure: Nothing to disclose.

Coauthor(s)

Abraham G Kocheril, MD, FACC, FACP, FHRS Professor of Medicine, University of Illinois College of Medicine

Abraham G Kocheril, MD, FACC, FACP, FHRS is a member of the following medical societies: American College of Cardiology, Central Society for Clinical and Translational Research, Heart Failure Society of America, Cardiac Electrophysiology Society, American College of Physicians, American Heart Association, American Medical Association, Illinois State Medical Society

Disclosure: Nothing to disclose.

Arnold S Baas, MD, FACC, FACP Associate Professor of Medicine, Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Ronald Reagan UCLA Medical Center

Arnold S Baas, MD, FACC, FACP is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, American Society of Echocardiography

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald J Oudiz, MD, FACP, FACC, FCCP Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American Thoracic Society, American College of Physicians, American Heart Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Actelion, Bayer, Gilead, Lung Biotechnology, United Therapeutics<br/>Received research grant from: Actelion, Bayer, Gilead, Ikaria, Lung Biotechnology, Pfizer, Reata, United Therapeutics<br/>Received income in an amount equal to or greater than $250 from: Actelion, Bayer, Gilead, Lung Biotechnology, Medtronic, Reata, United Therapeutics.

Chief Editor

Jeffrey N Rottman, MD Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine; Cardiologist/Electrophysiologist, University of Maryland Medical System and VA Maryland Health Care System

Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association, Heart Rhythm Society

Disclosure: Nothing to disclose.

Additional Contributors

Russell F Kelly, MD Assistant Professor, Department of Internal Medicine, Rush Medical College; Chairman of Adult Cardiology and Director of the Fellowship Program, Cook County Hospital

Russell F Kelly, MD is a member of the following medical societies: American College of Cardiology

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous authors Krishna Malineni, MD, and Peter A McCullough, MD, MPH, FACC, FACP, FCCP, to the development and writing of this article.

References
  1. Berdowski J, Blom MT, Bardai A, Tan HL, Tijssen JG, Koster RW. Impact of Onsite or Dispatched Automated External Defibrillator Use on Survival After Out-of-Hospital Cardiac Arrest. Circulation. 2011 Nov 15. 124(20):2225-32. [Medline].

  2. Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med. 2004 Jan. 8;350(2):105-13. [Medline].

  3. Holzer M. Targeted temperature management for comatose survivors of cardiac arrest. N Engl J Med. 2010 Sep 23. 363(13):1256-64. [Medline].

  4. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007 Aug. 21;147(4):251-62. [Medline].

  5. Mehra R. Global public health problem of sudden cardiac death. Journal of Electrocardiology. 2007 Nov-Dec. 40(6 Suppl):S118-22. [Medline].

  6. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation. 1989 Apr. 79(4):756-65. [Medline].

  7. Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J. 1987 Mar. 113(3):799-804. [Medline].

  8. Kuller LH. Sudden death--definition and epidemiologic considerations. Prog Cardiovasc Dis. 1980 Jul-Aug. 23(1):1-12. [Medline].

  9. Thompson RJ, McCullough PA, Kahn JK. Prediction of death and neurologic outcome in the emergency department in out-of-hospital cardiac arrest survivors. Am J Cardiol. 1998 Jan 1. 81(1):17-21. [Medline].

  10. Thompson RJ, McCullough PA, Kahn JK. Early prediction of death and neurologic outcome in out-of-hospital sudden death survivors in the emergency department. Circulation. 1996. 94:I-356.

  11. McCullough PA, Thompson RJ, Tobin KJ. Validation of a decision support tool for the evaluation of cardiac arrest victims. Clin Cardiol. 1998 Mar. 21(3):195-200. [Medline].

  12. Ikeda Y, Yutani C, Huang Y, et al. Histological remodeling in an ovine heart failure model resembles human ischemic cardiomyopathy. Cardiovasc Pathol. 2001 Jan-Feb. 10(1):19-27. [Medline].

  13. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000 Jan. 35(1):36-44. [Medline].

  14. Brooks A, Schinde V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic myocardium. Heart. 2003 Oct. 89(10):1255-6. [Medline].

  15. Fielitz J, Hein S, Mitrovic V, et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol. 2001 Apr. 37(5):1443-9. [Medline].

  16. Sovari AA, Cesario D, Kocheril AG, Brugada R. Multiple episodes of ventricular tachycardia induced by silent coronary vasospasm. J Interv Card Electrophysiol. 2008 Apr. 21(3):223-6. [Medline].

  17. Chizner MA, Pearle DL, deLeon AC. The natural history of aortic stenosis in adults. Am Heart J. 1980 Apr. 99(4):419-24. [Medline].

  18. Haïssaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008 May 8. 358(19):2016-23. [Medline].

  19. Derval N, Simpson CS, Birnie DH, et al. Prevalence and Characteristics of Early Repolarization in the CASPER Registry Cardiac Arrest Survivors With Preserved Ejection Fraction Registry. J Am Coll Cardiol. 2011 Aug 9. 58(7):722-8. [Medline].

  20. Gollob MH, Redpath CJ, Roberts JD. The Short QT Syndrome Proposed Diagnostic Criteria. J Am Coll Cardiol. 2011 Feb 15. 57(7):802-12. [Medline].

  21. Giustetto C, Schimpf R, Mazzanti A, et al. Long-Term Follow-Up of Patients With Short QT Syndrome. J Am Coll Cardiol. 2011 Aug 2. 58(6):587-95. [Medline].

  22. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011 Jan. 32(2):169-76. [Medline].

  23. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 Apr. 15(4):380-3. [Medline].

  24. Merchant FM, Ikeda T, Pedretti RF, Salerno-Uriarte JA, Chow T, Chan PS, et al. Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death. Heart Rhythm. 2012 Aug. 9(8):1256-1264.e2. [Medline]. [Full Text].

  25. [Guideline] 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science. Circ. 2010 Nov 2. [Full Text].

  26. Neumar RW, Barnhart JM, Berg RA, et al. Implementation Strategies for Improving Survival After Out-of-Hospital Cardiac Arrest in the United States: Consensus Recommendations From the 2009 American Heart Association Cardiac Arrest Survival Summit. Circulation. 2011 Jun 21. 123(24):2898-2910. [Medline].

  27. Bobrow BJ, Spaite DW, Berg RA, Stolz U, Sanders AB, Kern KB. Chest compression-only CPR by lay rescuers and survival from out-of-hospital cardiac arrest. JAMA. 2010 Oct 6. 304(13):1447-54. [Medline].

  28. Adielsson A, Hollenberg J, Karlsson T, et al. Increase in survival and bystander CPR in out-of-hospital shockable arrhythmia: bystander CPR and female gender are predictors of improved outcome. Experiences from Sweden in an 18-year perspective. Heart. 2011 Sep. 97(17):1391-6. [Medline].

  29. Dumas F, Grimaldi D, Zuber B, et al. Is hypothermia after cardiac arrest effective in both shockable and nonshockable patients?: insights from a large registry. Circulation. 2011 Mar 1. 123(8):877-86. [Medline].

  30. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996 Dec. 26;335(26):1933-40. [Medline].

  31. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar. 21;346(12):877-83. [Medline].

  32. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004 May. 20;350(21):2151-8. [Medline].

  33. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan. 20;352(3):225-37. [Medline].

  34. Bardy GH, Lee KL, Mark DB, et al. Home Use of Automated ExternalDefibrillators for Sudden Cardiac Arrest. N Engl J Med. 2008 Apr. 24;358(17):1793-804. [Medline].

  35. Altemose GT, Buxton AE. Idiopathic ventricular tachycardia. Annu Rev Med. 1999. 50:159-77. [Medline].

  36. Anderson KP, Freedman RA, Mason JW. Sudden death in idiopathic dilated cardiomyopathy. Ann Intern Med. 1987 Jul. 107(1):104-6. [Medline].

  37. Antiarrhythmics Versus Implantable Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997 Nov 27. 337(22):1576-83. [Medline].

  38. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989 Jan. 117(1):151-9. [Medline].

  39. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol. 1993 Jun. 4(3):356-68. [Medline].

  40. Benditt DG, Pritchett LC, Smith WM, et al. Characteristics of atrioventricular conduction and the spectrum of arrhythmias in Lown-Ganong-Levine syndrome. Circulation. 1978 Mar. 57(3):454-65. [Medline].

  41. Berger S, Dhala A, Friedberg DZ. Sudden cardiac death in infants, children, and adolescents. Pediatr Clin North Am. 1999 Apr. 46(2):221-34. [Medline].

  42. Beta-blocker Heart Attack Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982 Mar 26. 247(12):1707-14. [Medline].

  43. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997 Nov 27. 337(22):1569-75. [Medline].

  44. Bigger JT, Fleiss JL, Kleiger R. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984 Feb. 69(2):250-8. [Medline].

  45. Blackstone EH, Kirklin JW. Death and other time-related events after valve replacement. Circulation. 1985 Oct. 72(4):753-67. [Medline].

  46. Bromberg BI, Lindsay BD, Cain ME. Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1996 Mar 1. 27(3):690-5. [Medline].

  47. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998 Feb 10. 97(5):457-60. [Medline].

  48. Brugada P, Brugada J. A distinct clinical and echocardiographic syndrome: right bundle branch block, persistent ST segment elevation with normal QT interval and sudden cardiac death. PACE. 1991. 14:746-51.

  49. Brugada R, Hong K, Cordeiro JM. Short QT syndrome. CMAJ. 2005. 173(11):1349-54.

  50. Burkart F, Pfisterer M, Kiowski W. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990 Dec. 16(7):1711-8. [Medline].

  51. Burke AP, Farb A, Malcom GT. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997 May 1. 336(18):1276-82. [Medline].

  52. Cairns JA, Connolly SJ, Roberts R. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997 Mar 8. 349(9053):675-82. [Medline].

  53. Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989 Aug 10. 321(6):406-12. [Medline].

  54. Chang D, Goldstein S. Sudden cardiac death in ischemic heart disease. Compr Ther. 1997 Feb. 23(2):95-103. [Medline].

  55. Corrado D, Basso C, Thiene G. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997 Nov 15. 30(6):1512-20. [Medline].

  56. Davies MJ. The investigation of sudden cardiac death. Histopathology. 1999 Feb. 34(2):93-8. [Medline].

  57. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984 May 3. 310(18):1137-40. [Medline].

  58. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997 Nov 15. 30(6):1500-5. [Medline].

  59. DeRose JJ, Banas JS, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 1994 May-Jun. 36(6):475-84. [Medline].

  60. Domanski MJ, Zipes DP, Schron E. Treatment of sudden cardiac death. Current understandings from randomized trials and future research directions. Circulation. 1997 Jun 17. 95(12):2694-9. [Medline].

  61. Doval HC, Nul DR, Grancelli HO. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA- GEMA Investigators. Circulation. 1996 Dec 15. 94(12):3198-203. [Medline].

  62. Doyle JT, Kannel WB, McNamara PM. Factors related to suddenness of death from coronary disease: combined Albany-Framingham studies. Am J Cardiol. 1976 Jun. 37(7):1073-8. [Medline].

  63. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol. 1985 Jun. 5(6 Suppl):118B-121B. [Medline].

  64. Echt DS, Liebson PR, Mitchell LB. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21. 324(12):781-8. [Medline].

  65. Ehtisham J, Watkins H. Is Wolff-Parkinson-White syndrome a genetic disease?. J Cardiovasc Electrophysiol. 2005. 16(11):1258-62.

  66. Garson A, McNamara DG. Sudden death in a pediatric cardiology population, 1958 to 1983: relation to prior arrhythmias. J Am Coll Cardiol. 1985 Jun. 5(6 Suppl):134B-137B. [Medline].

  67. Gillum RF. Coronary heart disease in black populations. I. Mortality and morbidity. Am Heart J. 1982 Oct. 104(4 Pt 1):839-51. [Medline].

  68. Gilman JK, Jalal S, Naccarelli GV. Predicting and preventing sudden death from cardiac causes. Circulation. 1994 Aug. 90(2):1083-92. [Medline].

  69. Goldberger JJ. Treatment and prevention of sudden cardiac death: effect of recent clinical trials. Arch Intern Med. 1999 Jun 28. 159(12):1281-7. [Medline].

  70. Goldstein S. The necessity of a uniform definition of sudden coronary death: witnessed death within 1 hour of the onset of acute symptoms. Am Heart J. 1982 Jan. 103(1):156-9. [Medline].

  71. Goldstein S, Landis JR, Leighton R. Characteristics of the resuscitated out-of-hospital cardiac arrest victim with coronary heart disease. Circulation. 1981 Nov. 64(5):977-84. [Medline].

  72. Gottlieb SS. The use of antiarrhythmic agents in heart failure: implications of CAST. Am Heart J. 1989 Nov. 118(5 Pt 1):1074-7. [Medline].

  73. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013 Mar 6. 309(9):896-908. [Medline].

  74. Holmes DR, Davis KB, Mock MB. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation. 1986 Jun. 73(6):1254-63. [Medline].

  75. Iseri LT, Humphrey SB, Siner EJ. Prehospital brady-asystolic cardiac arrest. Ann Intern Med. 1978 Jun. 88(6):741-5. [Medline].

  76. Itoh H, Horie M, Ito M. Arrhythmogenesis in the short-QT syndrome associated with combined HERG channel gating defects: a simulation study. Circ J. 2006. 70(4):502-8.

  77. Jaoude SA, Leclercq JF, Coumel P. Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease. Eur Heart J. 1996 Nov. 17(11):1717-22. [Medline].

  78. Kunavarapu C, Bloomfield DM. Role of noninvasive studies in risk stratification for sudden cardiac death. Clin Cardiol. 2004. 27(4):192-7.

  79. Ladich E, Virmani R, Burke A. Sudden cardiac death not related to coronary atherosclerosis. Toxicol Pathol. 2006. 34(1):52-7.

  80. Latini R, Maggioni AP, Flather M. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995 Nov 15. 92(10):3132-7. [Medline].

  81. Lerman BB, Stein KM, Markowitz SM. Idiopathic right ventricular outflow tract tachycardia: a clinical approach. Pacing Clin Electrophysiol. 1996 Dec. 19(12 Pt 1):2120-37. [Medline].

  82. Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest in New York City. The Pre- Hospital Arrest Survival Evaluation (PHASE) Study. JAMA. 1994 Mar 2. 271(9):678-83. [Medline].

  83. Makikallio TH, Barthel P, Schneider R. Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol. 2006. 15;97(4):480-4.

  84. Marcus FI, Fontaine GH, Guiraudon G. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982 Feb. 65(2):384-98. [Medline].

  85. Maron BJ, Bonow RO, Cannon RO. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med. 1987 Apr 2. 316(14):844-52. [Medline].

  86. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986 Jan. 7(1):204-14. [Medline].

  87. Maron BJ, Shirani J, Poliac LC. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996 Jul 17. 276(3):199-204. [Medline].

  88. Maseri A, Severi S, Marzullo P. Role of coronary arterial spasm in sudden coronary ischemic death. Ann N Y Acad Sci. 1982. 382:204-17. [Medline].

  89. Metoprolol in Acute Myocardial Infarction Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo- controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985 Mar. 6(3):199-226. [Medline].

  90. Moss AJ. Prognosis after myocardial infarction. Am J Cardiol. 1983 Oct 1. 52(7):667-9. [Medline].

  91. Moss AJ, Schwartz PJ, Crampton RS. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991 Sep. 84(3):1136-44. [Medline].

  92. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Brunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia, Pa: WB Saunders; 1992:. 756-89.

  93. Myerburg RJ, Estes D, Zaman L. Outcome of resuscitation from bradyarrhythmic or asystolic prehospital cardiac arrest. J Am Coll Cardiol. 1984 Dec. 4(6):1118-22. [Medline].

  94. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992 Jan. 85(1 Suppl):I2-10. [Medline].

  95. Nademanee K, Singh BN, Stevenson WG. Amiodarone and post-MI patients. Circulation. 1993 Aug. 88(2):764-74. [Medline].

  96. Napolitano C, Bloise R, Priori SG. Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. J Cardiovasc Med (Hagerstown). 2006. 7(4):250-6.

  97. Narasimhan C, Jazayeri MR, Sra J. Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery. Circulation. 1997 Dec 16. 96(12):4307-13. [Medline].

  98. Neuspiel DR, Kuller LH. Sudden and unexpected natural death in childhood and adolescence. JAMA. 1985 Sep 13. 254(10):1321-5. [Medline].

  99. Prystowsky EN. Prevention of sudden cardiac death. Clin Cardiol. 2005. 28(11 Suppl 1):I12-8.

  100. Rosen MR, Jause MJ, Myerburg RJ. Arrhythmias induced by coronary artery occlusion: what are the electrophysiologic mechanisms? In: Hearse DJ, Mannings AS, Janse M, eds. Life-Threatening Arrhythmias During Ischemia and Infarction. New York, NY: Raven; 1987:. 11-47.

  101. Sarkozy A, Brugada P. Sudden cardiac death and inherited arrhythmia syndromes. J Cardiovasc Electrophysiol. 2005. 16 Suppl 1:S8-20.

  102. Schoenfeld MH, McGovern B, Garan H. Determinants of the outcome of electrophysiologic study in patients with ventricular tachyarrhythmias. J Am Coll Cardiol. 1985 Aug. 6(2):298-306. [Medline].

  103. Spirito P, Seidman CE, McKenna WJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997 Mar 13. 336(11):775-85. [Medline].

  104. Sra J, Akhtar M. Recent advances in understanding the mechanisms, diagnosis and treatment of congenital and acquired long QT syndrome. Indian Heart J. 1996 Nov-Dec. 48(6):639-51. [Medline].

  105. Stern S, Tzivoni D. Ventricular arrhythmias, sudden death, and silent myocardial ischemia. Prog Cardiovasc Dis. 1992 Jul-Aug. 35(1):19-26. [Medline].

  106. Stevenson WG, Stevenson LW, Middlekauff HR. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 1993 Dec. 88(6):2953-61. [Medline].

  107. Stiles S. Gd-Enhanced CMR Risk-Stratifies in Ischemics, Nonischemics; Clinical Value Uncertain. Medscape News. Mar 8 2013. Available at http://www.medscape.com/viewarticle/780491. Accessed: Mar 26 2013.

  108. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J. 1992 Oct. 124(4):1035-45. [Medline].

  109. Tapanainen JM, Lindgren KS, Makikallio TH. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol. 2004. 43(5):757-63.

  110. Viskin S, Lesh MD, Eldar M. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol. 1997 Oct. 8(10):1115-20. [Medline].

  111. Watkins H, McKenna WJ, Thierfelder L. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995 Apr 20. 332(16):1058-64. [Medline].

  112. Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am J Cardiol. 1974 Dec. 34(7):777-82. [Medline].

  113. Westenskow P, Splawski I, Timothy KW. Compound mutations: a common cause of severe long-QT syndrome. Circulation. 2004. 109(15):1834-41.

  114. Winslow RD, Mehta D, Fuster V. Sudden cardiac death: mechanisms, therapies and challenges. Nat Clin Pract Cardiovasc Med. 2005. 2(7):352-60.

  115. Yusuf S, Peto R, Lewis J. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr. 27(5):335-71. [Medline].

  116. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998 Nov 24. 98(21):2334-51. [Medline].

 
Previous
Next
 
Interplay of various risk factors that can lead to sudden cardiac death.
Cardiac death, sudden. Plots of mortality rates (deaths per 1000 persons) for ischemic heart disease occurring out of the hospital or in the emergency department (top) and occurring in the hospital (bottom) by age, sex, and race in 40 states during 1985.
Cardiac death, sudden. Figure a shows neurologic outcome stratified by initial cardiac arrest score. Neurologic recovery is defined as discharged home and able to care for self. Figure b shows overall survival stratified by initial cardiac arrest score.
Cardiac death, sudden. Epsilon wave in a patient with arrhythmogenic right ventricular dysplasia.
Cardiac death, sudden. Ventricular fibrillation appeared during rapid atrial fibrillation in a patient with Wolff-Parkinson-White syndrome.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.